Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 11/20 | 0.58 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | DHODH | Q02127 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2007335 | 0.81 | CYP2D6 (0.62) | TACR3PDE10ATSHRLMNADHODH | |
| SCHEMBL2013005 | 0.80 | TACR3 (0.59) | TACR3PDE10ATSHRLMNACYP2D6 | |
| SCHEMBL4993354 | 0.79 | LMNA (0.47) | TACR3PDE10ATSHRLMNA | |
| SCHEMBL4984967 | 0.79 | LMNA (0.47) | TACR3PDE10ATSHRLMNA | |
| SCHEMBL5048810 | 0.77 | LMNA (0.71) | TACR3LMNA | |
| SCHEMBL27745159 | 0.77 | TACR3 (0.60) | TACR3PDE10ATSHRLMNADHODH | |
| SCHEMBL8249659 | 0.76 | PDE10A (0.59) | TACR3PDE10ATSHRDHODHCYP2C19 | |
| SCHEMBL1581400 | 0.76 | TACR3 (0.75) | TACR3TSHRCYP2D6CYP2C19CYP3A4 | |
| SCHEMBL7686463 | 0.75 | TSHR (0.56) | TACR3PDE10ATSHRDHODHCYP2C19 | |
| SCHEMBL7686462 | 0.75 | TSHR (0.56) | TACR3PDE10ATSHRDHODHCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964733-B2 | to potentiate the effects of the other CNS agents; probes for the localization of cell surface receptors;3-(methylthio)-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide; depression, anxiety, schizophrenia, cognitive disorders, obesity, irritable bowel syndrome, emesis, pre-eclampsia, etc. | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | disclosed |
| US-20080214605-A1 | Alkyl Sulfoxide Quinolines as Nk-3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214605-A1 | Alkyl Sulfoxide Quinolines as Nk-3 Receptor Ligands | MSR1, KCNQ3, KCNA3 | TACR3 13/4885PDE10A 3017/4885TSHR 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.